Michael D Mühlebach


Country: Germany


  1. Nürnberger C, Bodmer B, Fiedler A, Gabriel G, Mühlebach M. A measles virus-based vaccine candidate mediates protection against Zika virus in an allogenic mouse pregnancy model. J Virol. 2018;: pubmed publisher
  2. Gogesch P, Schülke S, Scheurer S, Mühlebach M, Waibler Z. Modular MLV-VLPs co-displaying ovalbumin peptides and GM-CSF effectively induce expansion of CD11b+ APC and antigen-specific T cell responses in vitro. Mol Immunol. 2018;101:19-28 pubmed publisher
    ..These data suggest MLV-VLPs to be an attractive platform to flexibly combine antigen and adjuvant for novel modular vaccination approaches. ..
  3. Bodmer B, Fiedler A, Hanauer J, Prüfer S, Mühlebach M. Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model. Virology. 2018;521:99-107 pubmed publisher
  4. Uhlig K, Schülke S, Scheuplein V, Malczyk A, Reusch J, Kugelmann S, et al. Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response. J Virol. 2015;89:9044-60 pubmed publisher
    ..Thereby, the potential for easy envelope exchange allows the circumventing of neutralizing antibodies, e.g., during repeated boost immunizations. ..
  5. Malczyk A, Kupke A, Prüfer S, Scheuplein V, Hutzler S, Kreuz D, et al. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. J Virol. 2015;89:11654-67 pubmed publisher
    ..Subsequent challenge experiments indicated protection of vaccinated animals, illustrating the potential of MV as a vaccine platform with the potential to target emerging infections, such as MERS-CoV. ..
  6. Hutzler S, Erbar S, Jabulowsky R, Hanauer J, Schnotz J, Beissert T, et al. Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles. Sci Rep. 2017;7:16892 pubmed publisher
    ..These data indicate the potential of MV to trigger selected tumor antigen-specific immune responses on top of direct tumor lysis for enhanced efficacy. ..
  7. Mühlebach M, Hutzler S. Development of Recombinant Measles Virus-Based Vaccines. Methods Mol Biol. 2017;1581:151-168 pubmed publisher
  8. Mühlebach M. Vaccine platform recombinant measles virus. Virus Genes. 2017;53:733-740 pubmed publisher
    ..Thereby, recombinant measles vaccines expressing additional antigens are a promising platform for future vaccines. ..